Improved heart failure by Rhein lysinate is associated with p38MAPK pathway

  • Authors:
    • Wei Wang
    • Xin Meng
    • Jing Wang
    • Yong Li
  • View Affiliations

  • Published online on: July 9, 2018     https://doi.org/10.3892/etm.2018.6423
  • Pages: 2046-2051
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to explore the role of Rhein lysinate (RHL) in neonatal rat ventricular myocytes (NRVMs) and congestive heart failure induced by co‑arctation of the abdominal aorta. Male Sprague‑Dawley rats were divided into 3 groups randomly: co‑arctation of abdominal aorta group (A group, n=10), sham operation group (SH group, n=10) and RHL treatment rats (A+RHL group, n=10). To establish an in vitro oxidative stressed cardiomyocyte model, NRVMs were treated with 10 µM H2O2 for 24 h. MTT assay indicated that H2O2 treatment reduced primary cardiomyocyte viability in a time‑ and dose‑ dependent manner, whereas RHL abolished the detrimental effects of H2O2, indicating a protective role of RHL. Further study demonstrated that H2O2‑induced reactive oxygen species (ROS) production was reversed by RHL. Then, TUNEL staining was carried out and the results revealed that H2O2 markedly enhanced primary cardiomyocyte apoptosis. Conversely, RHL incubation decreased H2O2‑induced cell apoptosis, indicating the protective role of RHL in primary cardiomyocytes. Furthermore, abnormal p38 activation was identified in the failed heart. Notably, treatment with RHL reduced p38 activation. In addition, RHL significantly enhanced the expression of anti‑apoptotic protein, B cell lymphoma (Bcl)‑2, however markedly reduced the protein level of Bcl‑2 associated X, apoptosis regulator in primary cardiomyocytes, indicating its anti‑apoptotic role in the cardiac setting. Overall, RHL protects heart failure primarily by reducing ROS production and cardiomyocyte apoptosis via suppressing p38 mitogen activated protein kinase activation.
View Figures
View References

Related Articles

Journal Cover

September-2018
Volume 16 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang W, Meng X, Wang J and Li Y: Improved heart failure by Rhein lysinate is associated with p38MAPK pathway. Exp Ther Med 16: 2046-2051, 2018.
APA
Wang, W., Meng, X., Wang, J., & Li, Y. (2018). Improved heart failure by Rhein lysinate is associated with p38MAPK pathway. Experimental and Therapeutic Medicine, 16, 2046-2051. https://doi.org/10.3892/etm.2018.6423
MLA
Wang, W., Meng, X., Wang, J., Li, Y."Improved heart failure by Rhein lysinate is associated with p38MAPK pathway". Experimental and Therapeutic Medicine 16.3 (2018): 2046-2051.
Chicago
Wang, W., Meng, X., Wang, J., Li, Y."Improved heart failure by Rhein lysinate is associated with p38MAPK pathway". Experimental and Therapeutic Medicine 16, no. 3 (2018): 2046-2051. https://doi.org/10.3892/etm.2018.6423